Thymosin Alpha-1
Thymalfasin, Tα1, TA1, Zadaxin (brand)
The Ground Truth Score
four plain questions, never one numberA real approved drug abroad; honest human evidence, modest biohacker payoff
Bottom line
Thymosin Alpha-1 is the rare gray-market-popular peptide that is genuinely an approved pharmaceutical (Zadaxin) in 35+ countries with multiple human RCTs and a benign safety record, but it is NOT FDA-approved, its proven wins are in sick patients (hepatitis, sepsis, immune-compromised), and its value for healthy "immune-boosting" use is largely unproven.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
Approved abroadA medicine elsewhere, not hereApproved and prescribed as a medicine in other countries, but not by FDA. That is real evidence a regulator somewhere reviewed it, and it is worth weighing. It is not a US route, and it does not mean the version sold to you domestically is that same reviewed product.
An approved pharmaceutical (Zadaxin) in 35+ countries with multiple human RCTs, but NOT FDA-approved. It holds FDA orphan-drug DESIGNATION, which is a development incentive and not a marketing approval, and the two get conflated constantly. Its proven wins are in sick patients (hepatitis, sepsis, immune compromise), not healthy immune-boosting.
Legal status as of 2026-06-16. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Clinically (thymalfasin/Zadaxin), the studied regimen is typically 1.6 mg subcutaneously twice weekly for chronic hepatitis B, given over months; sepsis and other protocols have used higher/more-frequent dosing.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Human use dates to the late 1970s/early 1980s: Thymosin Alpha-1 was isolated from thymosin fraction 5 by Goldstein and colleagues in 1972 and entered human immunodeficiency and hepatitis studies within the decade. Unlike most gray-market peptides, controlled human trials are abundant, over 30 clinical trials enrolling 11,000+ subjects, and it has been a marketed prescription drug (thymalfasin/Zadaxin) since the 1990s.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Synthetic version of a natural 28-amino-acid thymic peptide that modulates (rather than blindly stimulates) the immune system via Toll-like receptor signaling.
- Approved as the prescription drug thymalfasin (Zadaxin) in more than 35 countries for chronic hepatitis B and C and as an immune adjunct in cancer care.
- Studied as an adjuvant to improve vaccine response and to restore T-cell counts in immune-compromised and critically ill patients.
- Among the best-documented peptides for safety, with adverse-reaction data in thousands of treated subjects and injection-site reactions as the dominant complaint.
- Biohackers use it off-label for fewer/shorter infections and general immune resilience, though this healthy-user benefit is not what the approvals are based on.
The data behind each bullet
What actually backs it
Approved as a prescription drug (thymalfasin/Zadaxin) in 35+ countries for chronic hepatitis B and C, a regulatory approval grounded in human RCTs.
International marketing approval (not US) plus pivotal hepatitis RCTs reporting markedly higher virological response vs. control. This is real, repeated human evidence, the basis for an A-grade science rating.
PubMed: thymosin alpha 1 hepatitis B randomized trial ↗NOT FDA-approved in the United States. It holds FDA orphan-drug DESIGNATION (hepatitis B, hepatocellular carcinoma, melanoma, DiGeorge), which is a development incentive, not marketing approval. In the US it is investigational/gray-market.
Designation-vs-approval distinction confirmed across regulatory summaries and the comprehensive literature review; full US marketing approval was never obtained.
PMC7747025. Thymosin alpha 1: a comprehensive review ↗For sepsis, the largest and best-designed RCT (TESTS, n=1,106, multicentre, double-blind, placebo-controlled, phase 3) found NO clear reduction in 28-day all-cause mortality. A possible signal in older/chronically-ill subgroups is hypothesis-generating only.
Published phase-3 RCT (BMJ, 2025). A high-quality negative primary result, exactly the kind of evidence that tempers the hype.
PubMed PMID 39814420. TESTS sepsis phase 3 trial ↗Studied during COVID-19 to restore lymphocyte counts and modulate immunity; results were mixed and at least one study found no benefit for restoring CD4+/CD8+ T-cell counts.
Multiple registered human trials (e.g., ClinicalTrials.gov) plus observational/RCT data with inconsistent outcomes; net signal weak and confounded by pandemic-era standard of care.
ClinicalTrials.gov NCT04487444, thymalfasin for COVID-19 ↗The marketed healthy-user benefit ('boosts immunity / fewer colds' in well people) is essentially unproven by controlled trials; nearly all rigorous evidence is in DISEASED or immune-compromised populations.
No placebo-controlled trial demonstrates the everyday immune-resilience claim in healthy adults; that gap is the honest center of the page.
PubMed: thymosin alpha 1 healthy immune ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
No non-blood tracker exists — the only objective readout is immune bloodwork (ALC, CD4/CD8, NK), and even that moves only from a depleted baseline.
Bloodwork
A lab moves, but it's noisy, indirect, or off-target — treat it as a hint, not proof.
Thymosin-alpha-1 acts directly on immune cells (promotes thymic T-cell output, reverses T-cell exhaustion via lower PD-1/Tim-3), so its action CAN surface on routine labs as rising lymphocyte and CD4/CD8 counts. But this is documented only when there is a baseline deficit to correct (lymphopenia, low CD4), and only in critically ill cohorts (severe COVID, sepsis). In an immunocompetent person with normal counts there is usually nothing measurable to move, so blood cannot confirm the everyday immune-resilience claim.
Only informative if baseline is lymphopenic: ALC climbs back toward/into the normal range. In a user who starts with a normal count, expect little to no change, and a flat result is NOT proof of effect or failure.
Ta1 drives thymic T-cell output and expansion, restoring circulating lymphocytes in deficit states (shown in severe COVID and sepsis cohorts, PMID 32442287 / 23327199).
Only in those who begin low: rise in CD4+/CD8+ toward normal (COVID data showed restoration specifically when CD4 <650/uL or CD8 <400/uL). Effect is inconsistent or absent in non-lymphopenic subjects, and at least one COVID cohort saw no CD4/CD8 benefit.
Ta1 promotes T-cell maturation and reverses exhaustion, increasing helper/cytotoxic T cells when they are depleted.
Draw baseline
Before first dose - and critically, capture a documented ALC and CD4/CD8 count so you know whether a deficit even exists to correct. Without a low baseline there is usually nothing to track.
Retest
4-6 weeks (T-cell reconstitution takes weeks); draw at the same time of day and not during an acute illness.
Read this before you spend on labs
This only functions as verification if your baseline shows an immune deficit (lymphopenia or low CD4). In an immunocompetent person with normal counts, Ta1 typically produces NO measurable bloodwork change, and no placebo-controlled trial has shown the everyday immune-resilience claim in healthy adults via objective labs - so a flat retest does not confirm or refute the marketed benefit. Both surviving markers were validated only in critically ill deficit populations (severe COVID, sepsis), not healthy users. Lymphocyte counts are noisy (acute infection, physiologic stress, cortisol, diurnal variation, recent vaccination), and they track immune-cell NUMBERS, not the clinical endpoints that matter (viral clearance, fewer infections, survival). Results are inconsistent across cohorts. Grade is partial, not direct.
- Liu Y et al. Thymosin Alpha 1 Reduces the Mortality of Severe COVID-19 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020 (PMID 32442287) ↗
- Wu J et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013 (PMID 23327199) ↗
Bottom line
Thymosin-alpha-1 is a T-cell/immune modulator, so its only objective efficacy signal is immunologic and blood-borne (absolute lymphocyte count, CD4/CD8 ratio, NK cells) — already captured, at partial strength, by the blood finding. Critically, those counts rise toward normal only from a lymphopenic/immunocompromised baseline (severe COVID, sepsis, hepatitis, cancer); in an immunocompetent person with normal counts there is typically nothing to move, so even the blood readout can look flat while the peptide is pharmacologically active. No consumer or standard-lab non-blood modality applies: urine, stool (fecal calprotectin/microbiome), sleep/HRV wearables, CGM, VO2max, DEXA, genetic testing, and body-composition metrics have no validated link to Tα1 efficacy in humans. The biohacker use case (immune resilience, fewer colds) is subjective and unproven by controlled trials, with no objective proxy. Disease-specific outcomes that do track it — HBV DNA / HCV RNA viral load, ALT/AST, seroconversion, antibody titers — are themselves blood/serum tests, not a separate modality. Honest bottom line: outside of blood immune counts read against a depleted baseline, there is no objective way to verify this peptide is working.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Mechanism is comparatively well-characterized for a peptide (it is an approved drug abroad, so 'assumed' applies mainly to the healthy-user use case). Thymosin Alpha-1 acts as an agonist at Toll-like receptors, principally TLR2 and TLR9 (with TLR4 also implicated), on myeloid and plasmacytoid dendritic cells. This drives dendritic-cell and T-cell maturation/differentiation (CD4+/CD8+) and modulates cytokines (IFN-gamma, IL-2, IL-10), shifting immune tone rather than simply ramping it up. It is best described as an immune MODULATOR/restorer, which is why its clearest wins are in immune-suppressed states.
Dosing & handling
What users and clinicians report
Clinically (thymalfasin/Zadaxin), the studied regimen is typically 1.6 mg subcutaneously twice weekly for chronic hepatitis B, given over months; sepsis and other protocols have used higher/more-frequent dosing. Off-label community reports cluster around 1.6 mg subcutaneously twice weekly, with some running ~1.6-3.2 mg/week in divided doses, often in multi-week 'immune' blocks. Supplied as a lyophilized powder for reconstitution.
All non-prescription dosing is REPORTED, not prescribed. US 'research' vials are unregulated for identity, purity, sterility, and actual peptide content, so the number on the label may not be what is in the vial. The 1.6 mg figure comes from hepatitis trials in sick patients and should not be read as a validated 'wellness' dose. Anyone with autoimmune disease, on immunosuppression, pregnant/nursing, or with a serious medical condition should involve a physician, this is an immune-active compound, not a benign supplement.
Timing & food
Timing is not tightly tied to meals because it is injected subcutaneously and works through immune signaling rather than nutrient absorption, so fasted-vs-fed is not a meaningful lever; consistency of the twice-weekly schedule matters more than time of day. The clinical rationale for fixed twice-weekly dosing is the short ~2-3 h half-life paired with durable downstream immune effects, so spacing maintains the modulatory signal without daily injections.
Half-life
Short: peak blood level at roughly 1-2 hours with an elimination half-life of about 2-3 hours, and no meaningful accumulation between twice-weekly doses. The short half-life is why dosing is repeated rather than once-and-done; experimental Fc-fusion constructs (Tα1-Fc, ~25 h in mice) exist specifically to extend it but are not the marketed product.
Reconstitution sensitivity
Supplied as a lyophilized (freeze-dried) powder; reconstitute with bacteriostatic or sterile water and keep refrigerated after mixing. As a peptide it is sensitive to heat, light, repeated freeze-thaw, and agitation, gentle swirling rather than shaking. Community reports specifically cite storage failures (degraded/inactive vials) as a real-world problem, and unregulated 'research' supply makes correct cold-chain handling and verified content uncertain.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate-to-high for a peptide: it is a long-discussed compound with substantial forum activity (r/Peptides and similar), and at least one analysis claimed its threads out-engage even BPC-157/TB-500. Practitioner (longevity/functional-medicine clinic) discussion is also relatively heavy because of its drug pedigree.
Consistency
Reasonably consistent in direction but modest in magnitude: users commonly report fewer or shorter infections, less seasonal illness, and a vague 'more resilient' feeling over 2-4 weeks. Reports are tempered by frequent acknowledgement that the effect is subtle, hard to self-measure, and easily confounded, and by complaints about sourcing/storage rather than about the molecule failing.
Source credibility
Mixed credibility: a meaningful share of online content is vendor- or affiliate-adjacent and was discounted. However, the underlying compound has genuine peer-reviewed and regulatory backing, so the anecdote sits on top of a real (if disease-focused) evidence base, unusual for this category. The healthy-user signal still remains anecdote, not proof.
- Anecdote: many users report getting sick less often or recovering faster from colds/flu after a few weeks of twice-weekly dosing, while describing the effect as subtle and hard to quantify.
- Anecdote: it is generally praised as one of the better-tolerated peptides, with stinging/redness at the injection site being the most common complaint and few systemic effects.
- Anecdote: recurring frustration centers on sourcing and storage, users report wide quality variance between vendors and worry about degraded or under-dosed gray-market vials rather than about the peptide itself.
- Anecdote: people with autoimmune tendencies are noticeably cautious in community discussion, with some reporting they avoid it or stop it out of concern about over-stimulating an already-active immune system.
Placebo risk, Low
Placebo risk is rated LOW because the compound's validated endpoints are objective and measurable, hepatitis viral response, lymphocyte/T-cell counts, and 28-day mortality in RCTs, not just 'I feel better.' The caveat is that the off-label HEALTHY-user benefit (fewer colds, more resilience) IS largely subjective and unmeasured at home, so for the biohacker use case specifically the placebo contribution could be higher; the low rating reflects the drug's overall objective evidence base, not the wellness anecdote.
Risk panel
What could go wrong
Adverse events
In thousands of treated subjects the dominant adverse event is mild, transient injection-site reaction (redness, swelling, pain), generally resolving within hours to days and occurring in under ~5% of patients in hepatitis studies (markedly lower than interferon). Combined with interferon, rarer systemic effects (fever, fatigue, myalgia, nausea, neutropenia) have been reported, but these track largely to the interferon partner.
Theoretical concerns
As an immune modulator acting on Toll-like receptors (TLR2/TLR9) and driving T-cell and dendritic-cell activation, the theoretical concern is unwanted immune stimulation in people with autoimmune disease or those on immunosuppression (e.g., transplant recipients). Whether it could aggravate autoimmune conditions in otherwise-healthy biohackers is unstudied. It is described in the literature as immune-modulating rather than blindly immune-activating, which somewhat tempers this concern.
Contraindications
Caution/avoid in autoimmune disease, organ-transplant or other immunosuppressed states (theoretical interference), and known hypersensitivity. Not established as safe in pregnancy, breastfeeding, or children outside specific clinical indications. Use with immunosuppressants or other immunomodulators should be physician-supervised. None of this is formal label guidance for US use because it is not FDA-approved here.
Honest unknowns
Long-term (multi-year) safety in HEALTHY users taking it for general immune resilience is essentially uncharacterized, trial safety data come from limited-duration courses in sick patients. Gray-market product identity/purity is a major real-world unknown: US-sold 'research' vials are unregulated, and community reports describe wide sourcing-quality variance and storage failures. Optimal dose, frequency, and cycling for non-clinical use are unvalidated.
Confound watch
Biohackers rarely run it alone: it is commonly stacked with BPC-157, TB-500, thymosin beta-4, KPV, or LL-37, and frequently started at the same time as sleep, diet, sauna, vitamin D, or other immune-support changes, all of which muddy attribution of any 'fewer colds' effect. In the clinical literature, hepatitis and cancer benefits were often measured in COMBINATION with interferon or chemotherapy, so monotherapy magnitude is harder to isolate.
History
Discovery → first use → status
- 1972Thymosin Alpha-1 isolated from thymosin fraction 5 by Goldstein and colleagues.
- 1977Amino-acid sequence of the 28-residue peptide characterized; synthetic production enables human study.
- 1990sSynthetic thymalfasin (Zadaxin) reaches market in multiple countries for chronic hepatitis B; SciClone develops it commercially.
- 2004FDA grants orphan-drug designation (e.g., hepatocellular carcinoma), a development incentive, not US marketing approval.
- 2013ETASS trial: single-blind RCT suggesting a mortality reduction in severe sepsis, encouraging but not definitive.
- 2020-2021COVID-19 trials launched (ClinicalTrials.gov); outcomes mixed, some showing no T-cell-count benefit.
- 2025TESTS phase-3 sepsis RCT (BMJ, n=1,106) reports NO clear 28-day mortality benefit, the most rigorous data to date, and negative on its primary endpoint.
Verification
The COA standard, applied
Cross-checked across a peer-reviewed comprehensive literature review (PMC7747025), the published TESTS phase-3 sepsis RCT (PubMed 39814420), ClinicalTrials.gov registrations (NCT04487444, NCT04428008), and regulatory summaries confirming 35+ country approval but US orphan-DESIGNATION-only status. Citation URLs use real PubMed search-term and ClinicalTrials.gov/PMC endpoints; no PMIDs, titles, authors, or statistics were invented. Community-sentiment items are summarized as anecdote, not quoted.
The full verification standard →Sources
Where this comes from
- Thymosin alpha 1: A comprehensive review of the literature (PMC7747025) ↗· Peer-reviewed overview: mechanism (TLR2/9), 35+ country approval, orphan-drug designation, safety, indications.
- TESTS phase-3 sepsis RCT. PubMed PMID 39814420 ↗· Multicentre, double-blind, placebo-controlled phase 3 (n=1,106, BMJ 2025); NO clear 28-day mortality benefit.
- PubMed search, thymosin alpha 1 hepatitis B randomized trial ↗· Body of hepatitis B/C RCT evidence underpinning the international approval.
- ClinicalTrials.gov NCT04487444, thymalfasin for COVID-19 ↗· Registered human trial of thymosin alpha 1 in COVID-19; part of the mixed-result pandemic-era dataset.
- ClinicalTrials.gov NCT04428008, thymosin alpha 1 to prevent COVID-19 in dialysis patients ↗· Additional registered human trial in an immune-compromised population.
- PubMed search, thymosin alpha 1 sepsis meta-analysis ↗· Systematic reviews/meta-analyses contextualizing the sepsis signal alongside the negative TESTS primary endpoint.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.